MARKET

NURO

NURO

NeuroMetrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.008
-0.062
-5.76%
After Hours: 0.9900 -0.0184 -1.82% 18:14 04/07 EDT
OPEN
1.140
PREV CLOSE
1.070
HIGH
1.150
LOW
0.9799
VOLUME
108.25K
TURNOVER
--
52 WEEK HIGH
10.60
52 WEEK LOW
0.8120
MARKET CAP
1.46M
P/E (TTM)
-0.2214
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NURO stock price target is 50.00 with a high estimate of 50.00 and a low estimate of 50.00.

EPS

NURO News

More
  • LK, APA, DO and GMLP among midday movers
  • Seeking Alpha - Article · 5d ago
  • CRNC, APRN, ARNC and VVUS among midday movers
  • Seeking Alpha - Article · 6d ago
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
  • Benzinga · 03/13 11:52

Industry

Medical Equipment, Supplies & Distribution
-1.80%
Healthcare Equipment & Supplies
-1.46%

Hot Stocks

Symbol
Price
%Change

About NURO

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.
More

Webull offers kinds of Neurometrix Inc stock information, including NASDAQ:NURO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NURO stock news, and many more online research tools to help you make informed decisions.